MARKET WIREStockInvest.us • 9h ago
Compugen Stock Price Forecast. Should You Buy CGEN?StockInvest.us report covering Compugen Ltd. (CGEN) market action, institutional positioning, and fundamental catalysts.
Why CGEN Stock dropped -2.94% Today — RQD Quant Desk Flash
$1.98 -2.94% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.97
Compugen Ltd. (CGEN) earns a Roarable Rating of B+ (Buy) with 78/100 RQD Confidence. High-quality cash engine (87% profit margin, 85% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B+ • BUY
Cap $193.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CGEN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Compugen Ltd. (NASDAQ: CGEN) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 78/100 at a spot price of $1.98 (-2.94% 1D, market cap $193.0M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 18/20, and SEC Balance-Sheet Forensics 19/20. Across 1016 tracked Health Care issuers, CGEN ranks #23 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CGEN compare to DTIL and ARTV in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CGEN carries a Roarable B+ (78/100 RQD), trailing P/E of 5.5x, gross margin of 87.3%, and ROIC of 85.0%. By comparison, DTIL (Precision BioSciences Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $205.4M) and ARTV (Artiva Biotherapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $206.8M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CGEN?
▼
Per CGEN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001119774), Compugen Ltd. generated $72.8M in revenue (+161.1% YoY), $35.3M in net income, and $31.3M in free cash flow against $156.6M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.97 (-0.29%)🧬 Cannibal Buyback (-3.20% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 43.1% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 78/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.9% avg 90D alpha vs SPY • 70.6% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B+
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B · Rk A-
Each axis scored 0–20
12M PRICE TARGET CONE+9.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CGEN)Realized 20D OHLCV Swing Band: ±11%
Deterministic 5-Pillar Attribution (78/100 Composite)
🔍 WHY CGEN SCORES 78/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+19/20 pts (24% of score)
SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-3.20% YoY Shares)
▲ #2 Bullish Driver: Macro Regime Fit+18/20 pts (23% of score)
FRED Regime × Technicals: 30% of 52W Range • RSI-14 at 41.1 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Whale & Options Positioning12/20 pts (-8 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-8 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade A$2.13-8% Next Q
86
Q2 (-2Q)Grade A$1.96-1% Next Q
83
Q3 (-1Q)Grade A-$1.94+2.1% Next Q
81
CurrentGrade B+$1.98+7.9% Hist 90D α
78
Trajectory: A (86) → B+ (78)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the CGEN Bull Thesis Could Fail
Even with a 78/100 (B+) score, CGEN faces multiple-compression risk if 5.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-3.20% YoY Shares) — any gross margin slip below 84.8% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($2.32) or 200D SMA ($2.30) invalidates the momentum regime and cuts Target Base ($2.16) toward Bear Floor ($1.62).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CGEN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CGEN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CGEN Stock dropped -2.94% Today — RQD Quant Desk Flash
Compugen Ltd. (CGEN) dropped -2.94% to $1.98, trading at 30% of its 52-week range ($1.43 – $3.24). High-quality cash engine (87% profit margin, 85% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 30% of its 52-week range ($1.43 – $3.24) with RSI-14 at 41.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11% around $1.98 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B+ (Buy) backed by 87.3% gross margin and $31.3M annual free cash flow.
Live CGEN Headlines & Catalysts
MARKET WIREYahoo Finance • 12h ago
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development ConferenceYahoo Finance report covering Compugen Ltd. (CGEN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com • 15h ago
Stifel reiterates Compugen stock rating on ovarian trial updateInvesting.com report covering Compugen Ltd. (CGEN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 18h ago
Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026Yahoo Finance report covering Compugen Ltd. (CGEN) market action, institutional positioning, and fundamental catalysts.
CATALYSThttps://www.siam.in/ • 21h ago
Locafy Limited (LCFY) Slips 6.55% to $1.14 as Shares Press Toward Lower Support - Momentum Surge Alertshttps://www.siam.in/ report covering Compugen Ltd. (CGEN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 21d ago
HC Wainwright & Co. Reiterates Buy on Compugen, Maintains $4 Price TargetHC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Compugen (NASDAQ:CGEN) with a Buy and maintains $4 price target.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (CGEN Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CGEN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -25.56%▼ DESCENDING CHANNEL
2026-10-30O $2.02H $2.02L $1.92C $1.98VOL 255.4K
RES: $2.87SUP: $1.85SMA50: $2.32SMA200: $2.30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CGEN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
-12.3%/yr Implied 5Y Growth
vs. +161.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CGEN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CGEN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CGEN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CGEN)
Health Care Rank #23 of 1016
⚔️ DTIL vs CGEN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CGEN vs. DTIL, ARTV, PALI, IVVD)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Compugen Ltd. (CGEN) ranks #23 by composite RQD confidence (78/100, grade B+) and #581 by equity capitalization ($193.0M). Within this direct 5-issuer industry benchmark cohort, CGEN leads on earnings valuation at 5.5x trailing P/E, while CGEN leads on capital efficiency and profitability with 85.0% ROIC and 87.3% gross margin. CGEN currently leads its immediate peer cohort in composite quantitative strength at 78/100 (B+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CGEN
ACTIVE
Compugen Ltd. | B+ | 78/100 | 5.5x | 87.3% | 85.0% | -2.94% | $193.0M | Benchmark Subject |
| DTIL Precision BioSciences Inc. | E | 24/100 | — | — | -35.0% | -5.11% | $205.4M | /dtil-vs-cgen → |
| ARTV Artiva Biotherapeutics Inc. | D- | 39/100 | — | — | -35.0% | -0.95% | $206.8M | /artv-vs-cgen → |
| PALI Palisade Bio Inc. | D- | 43/100 | — | — | -35.0% | -2.52% | $207.4M | /pali-vs-cgen → |
| IVVD Invivyd Inc. | E | 30/100 | — | — | -35.0% | -3.37% | $177.4M | /ivvd-vs-cgen → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001119774In its most recent audited fiscal period (FY2025, filed 2025-12-31), Compugen Ltd. (CGEN) reported GAAP revenue of $72.8M (+161.1% vs. FY2024 revenue of $27.9M , and +117.5% cumulative change since FY2023) , GAAP net income of $35.3M, operating cash flow of $31.6M, and free cash flow of $31.3M (-36.7% YoY). On the balance sheet, CGEN closed FY2025 with $156.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $72.8M | $35.3M | $31.6M | $31.3M | $156.6M | — |
| FY2024 (FY) | 2024-12-31 | $27.9M | -$14.2M | $49.6M | $49.5M | $115.0M | — |
| FY2023 (FY) | 2023-12-31 | $33.5M | -$18.8M | -$35.9M | -$35.9M | — | — |
3. CGEN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Compugen Ltd. (NASDAQ: CGEN) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 78/100 at a spot price of $1.98 (-2.94% 1D, market cap $193.0M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 18/20, and SEC Balance-Sheet Forensics 19/20. Across 1016 tracked Health Care issuers, CGEN ranks #23 in composite RQD confidence.
How does CGEN compare to DTIL and ARTV in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CGEN carries a Roarable B+ (78/100 RQD), trailing P/E of 5.5x, gross margin of 87.3%, and ROIC of 85.0%. By comparison, DTIL (Precision BioSciences Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $205.4M) and ARTV (Artiva Biotherapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $206.8M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CGEN?
Per CGEN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001119774), Compugen Ltd. generated $72.8M in revenue (+161.1% YoY), $35.3M in net income, and $31.3M in free cash flow against $156.6M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CGEN trading relative to its 50-day, 200-day, and 52-week technical levels?
CGEN last traded at $1.98 (-2.94% on volume of 255,462 shares), positioning the stock -14.66% below its 50-day simple moving average ($2.32) and -13.91% below its 200-day simple moving average ($2.30). Across its 52-week range of $1.43 to $3.24, CGEN sits at the 30.4% percentile with a 14-day RSI of 41.1 (NEUTRAL RANGE) and an implied next-earnings move of ±11.0% ($1.76 to $2.20).
CGEN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CGEN stock moving today?
Why CGEN Stock dropped -2.94% Today — RQD Quant Desk Flash. High-quality cash engine (87% profit margin, 85% return on capital) with steady institutional support.
ROARABLE RATING BRIEF • RQD 78/100 (B+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
CGEN — Compugen Ltd.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:41:26Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, CGEN scores 78 out of 100, graded B+, with the verdict "Roarable Buy — Very Good Cash & Smart-Money Inflow." The five pillars are:
- Fundamental Cash Engine: 14 / 20. Per the RQD rating, this pillar reflects ROIC of 85% and an FCF yield of 16.24%. For a prospective investor, these are the strongest cash-generation signals in the dataset, though the pillar score sits below the maximum, indicating the cash engine is strong but not uniformly proven across the reported periods.
- Whale 13F Flow: 12 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. The score is the second-lowest of the five pillars. The holders section in the source data is empty, so the underlying 13F detail cannot be verified here.
- Insider Conviction: 19 / 20. Per the RQD rating, this pillar reflects a cluster of SEC Form 4 and Congressional PTR flow. This is the highest pillar score. The underlying transactions are not itemized in the source data, so the score cannot be traced to specific filings.
- Macro Regime Fit: 18 / 20. Per the RQD rating, this pillar reflects a beta of 1.0 and sector sensitivity. A beta of 1.0 implies market-level volatility relative to the broader market, which is a neutral rather than defensive profile.
- Forensic Balance Sheet: 15 / 20. Per the RQD rating, this pillar reflects an Altman Z-Score of 2.5, a Piotroski F-Score of 7/9, and a Debt/Equity ratio of 0.5. These figures point to a balance sheet that is sound but not pristine.
Investor implications, framed analytically: the upside drivers flagged by the rating are the cash-generation metrics and the insider-flow pillar. The valuation tradeoff is that the market data shows a P/E (TTM) of 5.5 and an EV/EBITDA of 3.2, which the source data does not contextualize against peers, so whether these multiples reflect mispricing or durable market skepticism cannot be determined from the data provided. The rating's weakest pillar (whale flow) and the absence of analyst coverage mean the score rests more heavily on company-level fundamentals and insider activity than on broad institutional validation.
Snapshot
Business
Compugen Ltd. (CGEN) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, the market capitalization is $0.2B. Per the market data, gross margin is 87.3%, operating margin is 43.1%, and net margin is 48.6%. Customer base and product specifics are not available in source data.
Recent Catalysts & News Wire Analysis
Per the recent news and catalysts section:
- Third quarter 2026 results release: The company is scheduled to release third quarter 2026 results on Monday, November 9, 2026. This is the nearest dated event in the source data.
- H.C. Wainwright AI-based drug discovery conference: The company is set to participate in a fireside chat at this conference.
- Stifel rating reiteration: Stifel reiterated its rating on the stock following an ovarian trial update. The direction of the rating and the content of the trial update are not detailed in the source data.
- Momentum-related wire item: A GREEN-flagged catalyst item concerns a different issuer, Locafy Limited (LCFY), and reports a decline of 6.55% to $1.14. It is listed under CGEN's related-symbol feed but does not describe a CGEN event.
- Remaining feed items: The StockInvest.us forecast item carries no specific fundamental content beyond its general description.
Per the butterfly supply-chain graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals.
Open Questions
- What are the specific terms, endpoints, and outcome of the ovarian trial update referenced in the Stifel item, and how do they bear on the company's revenue trajectory?
- What drove the swing from FY 2024 operating loss to FY 2025 operating income, and is the $31.3M FY 2025 FCF recurring or tied to one-time receipts?
- What is the FY 2025 debt balance, and what are the terms of any obligations, given the debt line is unavailable?
- Who are the institutional holders and insiders behind the RQD pillar scores, and what are the sizes and dates of those transactions?
- How do the 5.5 P/E and 3.2 EV/EBITDA compare with biotech peers, and what explains the 52-week decline from $3.24 to the current $1.98 range?
CGEN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Compugen Ltd. (CGEN) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE StockInvest.us • 9h ago
Compugen Stock Price Forecast. Should You Buy CGEN? StockInvest.us report covering Compugen Ltd. (CGEN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 12h ago
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference Yahoo Finance report covering Compugen Ltd. (CGEN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 15h ago
Stifel reiterates Compugen stock rating on ovarian trial update Investing.com report covering Compugen Ltd. (CGEN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 18h ago
Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026 Yahoo Finance report covering Compugen Ltd. (CGEN) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.siam.in/ • 21h ago
Locafy Limited (LCFY) Slips 6.55% to $1.14 as Shares Press Toward Lower Support - Momentum Surge Alerts https://www.siam.in/ report covering Compugen Ltd. (CGEN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 21d ago
HC Wainwright & Co. Reiterates Buy on Compugen, Maintains $4 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Compugen (NASDAQ:CGEN) with a Buy and maintains $4 price target.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
CGEN Bull vs. Bear Conversation Board — What's Your Call at $1.98?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CGEN 🐻 33% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH
🎯 Target: $2.34 (+18.2%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is CGEN (B+ • RQD 78/100) a Buy at $1.98?
Welcome to the CGEN (Compugen Ltd.) Roar Pit. Current RQD Composite is 78/100 (Roarable Buy — Very Good Cash & Smart-Money Inflow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to capital efficiency (85.0% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $1.52 (-23.2%)
Spot @ $1.98 Pump the brakes on CGEN — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on CGEN, but look at what you are paying: 5.5x trailing P/E with 87.3% gross margins. Unless Compugen Ltd. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH
🎯 Target: $2.40 (+21.2%)
Spot @ $1.98 CGEN cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on CGEN, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $1.98 (52-wk range $1.43 - $3.24), any beat on forward guidance forces shorts and underweight funds to chase.